Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Me

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/29/2026

1. V
2. KLAC
3. SPY
4. PYPL
5. CSGP
6. BE
7. SWKS
8. F
9. STX
10. META

Go back to Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Me
(NASDAQ: NVCR) Delayed: 15.20 -1.11 (6.81%)
Previous Close $16.31    52 Week High $28.95 
Open $16.06    52 Week Low $5.95 
Day High $16.39    P/E N/A 
Day Low $15.12    EPS $0.00 
Volume 1,506,337       

(NASDAQ: ZLAB) Delayed: 18.31 -0.31 (1.66%)
Previous Close $18.62    52 Week High $ 
Open $18.33    52 Week Low $ 
Day High $18.53    P/E N/A 
Day Low $18.10    EPS $ 
Volume 577,609